70/100B103.045
USD
2.09
(2.07%)
Market Open
Last updated: · Delayed 15 min
Fair value103.20Plus-0%77Price 103.05174
Q2 FY2027 · Earnings report
EPS estimate 1.33Revenue estimate 9.48B
Q2 FY2027 · Earnings report
EPS estimate 1.33Revenue estimate 9.48B
If you had invested in Medtronic ago, it would be worth $1,602 today, against $4,096 in SPY and $6,368 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
70/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2026; the price as of today.
Medtronic key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Dividend stock · 7.2/10Growth 3.3 · Value 6.3 · Dividend 7.2
- Day range
- 101.450 – 103.230
- 52-week range
- 73.310 – 106.330
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 131.81B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 25.19
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 1.50
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 4.09
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 2.79%
- EPS growth forecast (FY2027)
- +8.1%
- Volume
- 44,631
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.57
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 69.2/100Environment 77 · Social 66 · Governance 64
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha
- Employees
- 95K
- Website
- medtronic.com
- IPO date
- 2 May 1973
Medtronic earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q2 FY2027
EPS estimate
1.33 USD
Revenue estimate
9.48B USD
Last quarter · Q1 FY2027
EPS1.45Beat +4.3%Revenue9.76BBeat +2.2%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2028 | 1.47 | — | — | +1.56% | 9.80B | — | — | +0.45% | |
| Q4 FY2027 | 1.78 | — | — | +14.67% | 10.30B | — | — | +4.98% | |
| Q3 FY2027 | 1.43 | — | — | +4.81% | 9.52B | — | — | +5.63% | |
| Q2 FY2027 | 1.33 | — | — | -2.21% | 9.48B | — | — | +5.79% | |
| Q1 FY2027 | 1.39 | 1.45 | +4.32% | +15.08% | 9.55B | 9.76B | +2.20% | +13.73% | |
| Q4 FY2026 | 1.54 | 1.55 | +0.65% | -4.32% | 9.62B | 9.81B | +1.94% | +9.86% | |
| Q3 FY2026 | 1.34 | 1.36 | +1.49% | -2.16% | 8.91B | 9.02B | +1.19% | +8.74% | |
| Q2 FY2026 | 1.31 | 1.36 | +3.82% | +7.94% | 8.87B | 8.96B | +1.06% | +6.64% | |
| Q1 FY2026 | 1.23 | 1.26 | +2.44% | +2.44% | 8.38B | 8.58B | +2.38% | +7.17% | |
| Q4 FY2025 | 1.58 | 1.62 | +2.53% | +10.96% | 8.82B | 8.93B | +1.23% | +3.94% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2029 | 6.91 | — | — | +8.08% | 42.10B | — | — | +4.52% |
| FY2028 | 6.39 | — | — | +6.99% | 40.28B | — | — | +3.16% |
| FY2027 | 5.98 | — | — | +8.09% | 39.05B | — | — | +7.38% |
| FY2026 | 5.52 | 5.53 | +0.21% | +0.55% | 36.15B | 36.36B | +0.60% | +8.14% |
| FY2025 | 5.46 | 5.50 | +0.78% | +5.57% | 33.51B | 33.63B | +0.34% | +3.90% |
| FY2024 | 3.28 | 5.21 | +58.78% | -1.70% | 33.00B | 32.36B | -1.92% | +3.64% |
| FY2023 | 5.27 | 5.30 | +0.53% | -5.69% | 30.94B | 31.23B | +0.94% | -1.45% |
Analysts' estimates for FY2027 over the last 7 days:EPS Revenue How the estimates moved
Medtronic analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
97.73 USD
-5.16%
Analysts' 1-year price targets range from 83.00 to 115.00, with an average of 97.73.
Past year
1-year forecast
Strong sellStrong buy
Buy
22 ratings
| Buy | 16 | |
| Hold | 6 | |
| Sell | 0 |
12-month price target
| Highest target | 115.00 |
| Average target | 97.73 |
| Lowest target | 83.00 |
| Current price | 103.05 |
Medtronic valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 25.19
- Forward P/E (FY2027)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 17.24
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 3.51
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 2.62
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 14.85
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
131.81B USD
+
Total debt
28.15B USD
−
Cash and short-term investments
8.82B USD
=
Enterprise value
151.15B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Medtronic against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2022 to FY2026: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Stryker, Abbott Laboratories, Boston Scientific, Edwards Lifesciences, GE HealthCare Technologies, and DexCom, the US Medical - Devices companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Below its median25.219.641.0
- Gross marginLowest in 5 years65.0%65.0%68.0%Against its peers: 3 of 7Peers' median 62.0%
- Operating marginAbove its median17.8%15.9%18.2%Against its peers: 6 of 7Peers' median 19.5%
- Net marginAt its median13.2%11.4%15.9%Against its peers: 5 of 7Peers' median 14.5%
- Return on equityAbove its median9.7%7.3%9.7%Against its peers: 7 of 7Peers' median 13.5%
- Free cash flow marginBelow its median14.9%14.7%18.9%Against its peers: 6 of 7Peers' median 17.6%
- Revenue growthHighest in 5 years8.4%-1.4%8.4%Against its peers: 5 of 7Peers' median 11.4%
- EPS growthAt its median3.3%-24.4%40.2%Against its peers: 5 of 7Peers' median 6.5%
- Debt to EBITDAAt its median2.85×2.75×3.09×Against its peers: 7 of 7Peers' median 1.85×
- Current ratioAbove its median2.131.852.39Against its peers: 2 of 7Peers' median 1.75
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Medtronic growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 37.54B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 5.23B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 66.69%
- Operating margin
- 18.90%
- Net margin
- 13.93%
Revenue / Net income
Revenue Net income Net margin
Medtronic revenue breakdown
By product
FY2026
38.6%Cardiac and Vascular Group28.4%Neuroscience Group24.4%Medical Surgical8.6%Diabetes Group
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Cardiac and Vascular Group | 13.98B | 38.6% | +12.0% |
| Neuroscience Group | 10.29B | 28.4% | +4.5% |
| Medical Surgical | 8.82B | 24.4% | +4.9% |
| Diabetes Group | 3.11B | 8.6% | +13.0% |
By region
FY2026
79.6%United States20.2%Total Other Countries, Excluding United States and Ireland
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 71.40B | 79.6% | +315.8% |
| Total Other Countries, Excluding United States and Ireland | 18.12B | 20.2% | +11.5% |
| Ireland | 143.00M | 0.2% | +23.3% |
How Medtronic makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Cardiac and Vascular Group13.98B 38.4%
Neuroscience Group10.29B 28.3%
Medical Surgical8.82B 24.2%
Diabetes Group3.11B 8.6%
Revenue36.36B 100.0%
Cost of revenue12.72B 35.0%
Gross profit23.64B 65.0%
Research and development2.87B 7.9%
Selling and administration11.78B 32.4%
Other operating expenses2.52B 6.9%
Operating income6.47B 17.8%
Tax1.30B 3.6%
Other expense368.00M 1.0%
Net income4.80B 13.2%
FY2026, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2026, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Medtronic dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 2.88 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 2.79%
- Payout ratioWhat is the payout ratio? The payout ratio is the share of a company's earnings paid out as dividends: dividends per share divided by earnings per share (EPS).
- 69.93%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 44
- Frequency
- Quarterly
- Last payment
- 0.72 USD
- Last ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 25 Sept 2026
- Last payment date
- 16 Oct 2026
Dividends per share
Medtronic financial health
- Cash and short-term investments
- 8.82B USD
- Total debt
- 28.15B USD
- Net cash
- -19.33B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 6.13B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 2.07
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.56
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 9 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.16
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Medtronic ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 86.10%
- Institutional holders
- 2,209 (-105)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.91%
Who owns the shares
Institutions 86.1% Others 13.9%
As of 30 Jun 2026
Shares free to trade
Free float 1.28B shares ·99.9% Closely held 1.12M shares ·0.1%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 2 | 65.91K | 60.60K |
| Q3 2026 | 0 | 2 | 1.30M | 34.20K |
| Q2 2026 | 0 | 2 | 190.01K | 216.85K |
| Q1 2026 | 0 | 5 | 50.88K | 106.86K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling PrepVerified against SEC filings
Title: Medtronic plc
Sector: Healthcare
Industry: Medical - Devices
Medtronic Plc is a global medical device and healthcare company. The company’s main divisions are: Cardiovascular, Medical Surgical, Neuroscience and Diabetes. Its main customer segments include hospitals, physicians, clinicians and private patients. Medtronic Plc products include pacemakers and insertable cardiac monitors, among other items used for cardiovascular treatment. Its neuroscience range includes spinal implants, bone graft substitutes, biologic products, image-guided surgery, and more. Diabetes products include continuous glucose monitoring and smart insulin pen systems. The company's executive headquarters are in Minneapolis, Minnesota, while its legal headquarters are in Ireland.